Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …

Highlights•Anticancer drug resistance (ADR) is a primary clinical bottleneck for treatment of
cancers.•Immune checkpoint inhibitors (ICIs) have been revolutionized the treatment for …

This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic
NSCLC patients, aims to compare the efficacy of treatments including at least one immune …

In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in
different clinical studies. Currently, immunotherapy was clinically validated as effective …

Rationale: This study aimed to use computed tomography (CT) images to assess PD-L1
expression in non-small cell lung cancer (NSCLC) and predict response to immunotherapy …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Immune evasion is a key strategy adopted by tumor cells to escape the immune system
while promoting their survival and metastatic spreading. Indeed, several mechanisms have …